CKD (chronic kidney disease) is more common than previously thought, and has greater implications than previously thought. Most people with CKD fall into the mild to moderate categories where hospital-based management is not necessary. For many in this patient group, the cardiovascular impact of their renal disease is more significant than the risk of developing end stage renal failure.
Contents
Assessment of severity
Guidance is usefully directed according to severity of renal damage. The 5 K/DOQI CKD (chronic kidney disease) stages are useful. (KDOQI – Kidney Diseases Outcome Quality Initiative – more info)
Stage
|
GFR
|
Description
|
Treatment stage
|
1
|
90+
|
Normal kidney function but urine or other abnormalities point to kidney disease | Observation, control of blood pressure and CV risk factors – see below for management |
2
|
60-89
|
Mildly reduced kidney function, urine or other abnormalities point to kidney disease | Observation, control of blood pressure and CV risk factors – see below for management |
3
|
30-59
|
Moderately reduced kidney function | More of the above, plus diagnosis, if indicators of poorer prognosis. – see below for management
|
4
|
15-29
|
Severely reduced kidney function | Planning for endstage renal failure – see info for Stage 3, plus note on stage 4 below. (Also available – more info on dialysis etc for patients) |
5
|
14 or less
|
Very severe, or endstage kidney failure (sometimes called established renal failure) | (Also available, more info on treatment choices for endstage renal failure, primarily for patients.) |
The K/DOQI stages depend on knowledge of GFR, or more usually, estimation of GFR from serum creatinine (eGFR). This is useful because using serum creatinine alone can give a misleading impression (usually too optimistic) of renal function, although eGFR has its weaknesses – particularly, lack of precision. More information about eGFR (estimated GFR) from the UK CKD Guidelines, and More info about eGFR from the EdREN handbook.
Risks of CKD and CRF
Having signs of kidney disease, even just proteinuria, increases the risk of
- Developing end stage renal failure
- Cardiovascular death
Although the risk of developing end stage renal failure increases progressively as you move through the stages of CKD, on a population-wide basis the increased cardiovascular risk is numerically even more significant.
Management of stages 1 and 2 CKD |
Stages 1 and 2 kidney disease: Normal or mildly impaired renal function, with proteinuria or haematuria or other evidence of renal disease. In stage 1, GFR is normal; in stage 2 it is 60-90 mls/min/1.73m2 but note that stage 2 CKD requires more than just slightly reduced GFR – proteinuria or haematuria or other evidence of structural renal disease. The imprecision of eGFR may otherwise label many with normal renal function as falling into CKD stage 2. |
Initially
|
Long term management
|
Management of stage 3+ CKD |
Moderately impaired renal function (GFR 30-60). Management in the community is safe and sensible for many patients with stage 3 CKD (see referral guidelines). |
Initially
|
Long term management. In addition to measures for stages 1 and 2:
|
Management of stage 4+ CKD |
Severely impaired renal function (GFR <30 for stage 4, <15 for stage 5). Management will usually include at least discussion with the Renal Unit, but for patients in community, the box above provides appropriate advice. For medical staff seeking advice on patients in Lothian, rie.renaladvice@luht.scot.nhs.uk. More info on Stage 4/5 CKD from the UK CKD Guidelines |
Management of diabetes mellitus with proteinuria or microalbuminuria |
Refer to a renal unit in just the same circumstances as for patients with other types of CKD. See referral guidelines. However earlier management of patients with proteinuria/ microalbuminuria should be more aggressive – ACE inhibitors should be commenced if there is microalbuminuria even with normal blood pressure. |
Early management:
|
Refer if:
|
Summary of indications for measuring serume creatinine
At diagnosis and at least annually in all adult patients with:
- Established renal disease of all types, with or without established CKD, and those at increased risk, such as those with abnormal bladder function.
- Patients with proteinuria or urologically unexplained haematuria (possible glomerulonephritis)
- Hypertension
- Heart failure
- Coronary, cerebral or peripheral vascular disease
- Diabetes mellitus
- Patients taking diuretics, angiotensin converting enzymes, angiotensin receptor blockers
- Multisystem disease including SLE, rheumatoid arthritis, vasculitis